A medication can be studied alongside methamphetamine without being shown to protect someone from methamphetamine. That distinction matters when a laboratory interaction study is offered as evidence about the cause of an adverse event. The appropriate question is whether the research actually tested the protective effect being claimed.
What did the 2026 human experiment test?
Black and colleagues reported a randomized, double-blind, placebo-controlled inpatient crossover study in 15 participants with methamphetamine use disorder: 12 without opioid use and three receiving methadone maintenance. Oral mirtazapine 30 mg daily or placebo preceded a 30 mg intravenous methamphetamine challenge on the fifth day. Participants crossed to the opposite condition. This was an interaction study, not a treatment-efficacy trial.
Mirtazapine neither significantly reduced nor increased the measured cardiovascular response to methamphetamine. The heart-rate interaction estimate was −0.06 beats/minute, with a 95% confidence interval of −9.33 to 9.20. Methamphetamine peak plasma concentration occurred 0.26 hours earlier during mirtazapine exposure (P = .02); other pharmacokinetic effects were not observed. Adverse-event frequency and severity did not significantly differ. No serious adverse events or deaths occurred. Selection excluded unstable cardiovascular conditions; only three participants received methadone. The small sample and controlled challenge limit generalization.
Why is a null interaction different from protection?
Consider the claim, “The medication prevented the stimulant’s cardiac effects.” To support that proposition, a comparison must demonstrate a reduction in the relevant response. An estimate near zero for an interaction instead addresses whether the response changed detectably between conditions. Calling that protection reverses the question.
A confidence interval also belongs beside the point estimate. As a matter of statistical interpretation, failure to reject a zero interaction is different from demonstrating equivalence within a prespecified clinically acceptable margin. A reviewer should ask whether that margin was defined and tested before using the word “equivalent.”
How should this evidence be used in a forensic assessment?
The supplied historical review by Logan, published in 2002, describes methamphetamine effects across different doses, routes and patterns of use. It provides context for keeping those exposure details attached to an interpretation; it does not independently establish the safety of this medication combination.
For an individual case, first identify the proposition: an interaction, protection, treatment benefit, or attribution of an injury. Then identify the outcome needed to answer it. A physiological measurement, a treatment-retention endpoint and a cause-of-injury opinion cannot be substituted for one another merely because all involve the same drugs.
Useful records to request include the medication-administration timeline, specimen collection times, original cardiovascular observations and the basis for identifying the other substances involved. Those are proposed review steps, not findings that any particular patient experienced harm. This article does not recommend taking or combining medications.
Sources and evidence type
Black F, Santos GM, McMahan VM, et al. Safety of intravenous methamphetamine in patients taking mirtazapine: a two-site phase 1b randomized controlled trial. Journal of Clinical Psychopharmacology. 2026;46(4):404–411. Controlled human interaction experiment. DOI: 10.1097/JCP.0000000000002148. Full text.
Logan BK. Methamphetamine—Effects on Human Performance and Behavior. Forensic Science Review. 2002;14(1–2):133–151. Historical narrative review; supplied full text. Verified bibliographic record, PMID 26256490.